Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.
|Summary of New pCPA Activity Since Last Update
|Completed Negotiations (with LOI)
|Completed with No Agreement (with no LOI)
|Considerations at P/T Level
PDCI TARGET INSIGHTS (Since Last pCPA Update)
pCPA negotiations for 2019 ended with a slow December with no new drug products entering active negotiations.
- PREVYMIS closed negotiations after over one year of negotiations.
- LUTATHERA closed negotiations with no agreement after four months in negotiations.
- VITRAKVI did not enter negotiations after receiving negative CADTH and INESSS recommendations.
To find out more information about pCPA negotiations and how PDCI’s reimbursement strategy team
can help navigate through pCPA discussions, please contact Kaitlyn Proulx at firstname.lastname@example.org.